



CDC/IDSA COVID-19 Clinician Call

April 17, 2021

Welcome & Introduction

Dana Wollins, DrPH, MGC
Vice President, Clinical Affairs & Guidelines
IDSA

- 62nd in a series of weekly calls, initiated by CDC as a forum for information sharing among frontline clinicians caring for patients with COVID-19
- The views and opinions expressed here are those of the presenters and do not necessarily reflect the official policy or position of the CDC or IDSA. Involvement of CDC and IDSA should not be viewed as endorsement of any entity or individual involved.
- This webinar is being recorded and can be found online at www.idsociety.org/cliniciancalls.

TODAY'S CALL:

The Johnson & Johnson Vaccine: Current Situation & Anticipated Next Steps



Tom Shimabukuro, MD, MPH, MBA

Captain, U.S. Public Health Service
Deputy Director
Immunization Safety Office
Centers for Disease Control and Prevention



Sara Oliver, MD, MSPH

LCDR, U.S. Public Health Service
Co-Lead, COVID-19 Work Group of the Advisory Committee on Immunization
Practices
Centers for Disease Control and Prevention



Michael B. Streiff, MD

Medical Director
The Johns Hopkins Anticoagulation Management Service and
Hemostatic Disorder Stewardship Program
Johns Hopkins Special Coagulation Laboratory
Professor of Medicine & Professor of Pathology
Johns Hopkins University School of Medicine




John Su, MD, PhD, MPH

VAERS Team Lead
Centers for Disease Control and Prevention

Question?
Use the "Q&A" Button



Comment?
Use the "Chat" Button





Reports of cerebral venous sinus thrombosis with thrombocytopenia after Janssen COVID-19 vaccine

CDC/IDSA COVID-19 Clinician Call
April 17, 2021

Tom Shimabukuro, MD, MPH, MBA
CDC COVID-19 Vaccine Task Force
Vaccine Safety Team

Disclaimer

- The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC) or the U.S. Food and Drug Administration (FDA).
- Mention of a product or company name is for identification purposes only and does not constitute endorsement by CDC or FDA.

Topics

- Background
- Reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia (low platelets) following Janssen COVID-19 vaccine
- Summary

Background

Platelets and thrombocytopenia (low platelets)*

- Platelets (thrombocytes) are colorless blood cells that help blood clot; normal platelet count is 150,000–450,000 per microliter
- Platelets stop bleeding by clumping and forming plugs in blood vessel injuries
- Thrombocytopenia is a condition in which you have a low blood platelet count (<150,000 per microliter)
- Dangerous internal bleeding can occur when your platelet count falls below 10,000 platelets per microliter
- Though rare, severe thrombocytopenia can cause bleeding into the brain, which can be fatal

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

[Share](#)

News 07/04/2021

EMA confirms overall benefit-risk remains positive

EMA's safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).

In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group.

EMA is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination. So far, most of the cases reported have occurred in women under 60 years of age within 2 weeks of vaccination. Based on the currently available evidence, specific risk factors have not been confirmed.


People who have received the vaccine should seek medical assistance immediately if they develop symptoms of this combination of blood clots and low blood platelets (see below).

The PRAC noted that the blood clots occurred in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) and in arteries, together with low levels of blood platelets and sometimes bleeding.

The Committee carried out an in-depth review of 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis reported in the EU drug safety database (EudraVigilance) as of 22 March 2021, 18 of which were fatal.¹ The cases came mainly from spontaneous reporting systems of the EEA and the UK, where around 25 million people had received the vaccine.

COVID-19 is associated with a risk of hospitalisation and death. The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.

Janssen COVID-19 vaccine timeline* (2021)



* For illustrative purposes, not drawn to scale, [†] cerebral venous sinus thrombosis

**This is an official
CDC HEALTH ALERT**

Distributed via the CDC Health Alert Network
April 13, 2021, 1:00 PM ET
CDCHAN-00442

Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine

Summary

As of April 12, 2021, approximately 6.85 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine (Janssen) have been administered in the United States. The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) are reviewing data involving six U.S. cases of a rare type of blood clot in individuals after receiving the J&J COVID-19 vaccine that were reported to the Vaccine Adverse Events Reporting System (VAERS). In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women aged 18–48 years. The interval from vaccine receipt to symptom onset ranged from 6–13 days. One patient died. Providers should maintain a high index of suspicion for symptoms that might represent serious thrombotic events or thrombocytopenia in patients who have recently received the J&J COVID-19 vaccine. When these specific type of blood clots are observed following J&J COVID-19 vaccination, treatment is different from the treatment that might typically be administered for blood clots. Based on studies conducted among the patients diagnosed with immune thrombotic thrombocytopenia after the AstraZeneca COVID-19 vaccine in Europe, the pathogenesis of these rare and unusual adverse events after vaccination may be associated with platelet-activating antibodies against platelet factor-4 (PF4), a type of protein. Usually, the anticoagulant drug called heparin is used to treat blood clots. In this setting, the use of heparin may be harmful, and alternative treatments need to be given.

CDC will convene an emergency meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday, April 14, 2021, to further review these cases and assess potential implications on vaccine policy. FDA will review that analysis as it also investigates these cases. Until that process is complete, CDC and FDA are recommending a pause in the use of the J&J COVID-19 vaccine out of an abundance of caution. The purpose of this Health Alert is, in part, to ensure that the healthcare provider community is aware of the potential for these adverse events and can provide proper management due to the unique treatment required with this type of blood clot.

Background

VAERS is a national passive surveillance system jointly managed by CDC and FDA that monitors adverse events after vaccinations. The six patients (after 6.85 million vaccine doses administered) described in these VAERS reports came to attention in the latter half of March and early April of 2021 and developed symptoms a median of 9 days (range = 6–13 days) after receiving the J&J COVID-19 vaccine. Initial presenting symptoms were notable for headache in five of six patients, and back pain in the sixth who subsequently developed a headache. One patient also had abdominal pain, nausea, and vomiting. Four developed focal neurological symptoms (focal weakness, aphasia, visual disturbance) prompting presentation for emergency care. The median days from vaccination to hospital admission was 15 days (range = 10–17 days). All were eventually diagnosed with

Cerebral venous sinus anatomy




Figure 1 | **Anatomy of the cerebral venous system.** Diagram showing the main components of the cerebral venous system. Blue vessels represent the deep venous system.

Cerebral venous sinus thrombosis (CVST)

Background epidemiology¹⁻³

- Rare, 0.22–1.57 per 100,000, ~0.5-1% of all strokes
- Median age 37 years
- 8% of patients >65 years
- Female:male ratio of 3:1

Risk factors⁴

- Prothrombotic conditions (genetic or acquired)
- Oral contraceptives
- Pregnancy and the post-partum period
- Malignancy
- Infection
- Mechanical precipitants (lumbar puncture)

¹ Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. Ferro JM, Correia M, Pontes C, Baptista MV, Pita F, Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport) *Cerebrovasc Dis.* 2001;11(3):177.

² The incidence of cerebral venous thrombosis: a cross-sectional study. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. *Stroke.* 2012 Dec;43(12):3375-7..

³ Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study. Devasagayam S, Wyatt B, Leyden J, Kleinig T. *Stroke.* 2016 Sep;47(9):2180-2.

⁴ Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Saposnik G, et al. 2011;42(4):1158.

CVST signs and symptoms

- More common presentations
 - Isolated intracranial hypertension syndrome (headache with or without vomiting, papilledema, and visual problems)
 - Focal syndrome (focal deficits, seizures, or both)
 - Encephalopathy (multifocal signs, mental status changes, stupor, or coma)
- Rare presentations
 - Cavernous sinus syndrome
 - Subarachnoid hemorrhage
 - Cranial nerve palsies

Data source and case reports

VAERS is the nation's early warning system for vaccine safety



VAERS

Vaccine Adverse Event Reporting System

<http://vaers.hhs.gov>



Reports of CVST to VAERS after COVID-19 vaccines as of April 12, 2021

- **Janssen COVID-19 vaccine**
 - 6 reports of CVST with thrombocytopenia (platelet counts $<150\text{K}/\text{mm}^3$) following 6.86 million doses administered
 - Reporting rate of 0.87 cases per million doses administered
- **Pfizer-BioNTech COVID-19 vaccine**
 - 0 reports following 97.9 million doses administered
- **Moderna COVID-19 vaccine**
 - 3 reports following 84.7 million doses administered
 - All 3 with normal platelet counts; onset 2, 6, and 12 days after vaccination

Reports of CVST to VAERS after COVID-19 vaccines as of April 12, 2021

- **Janssen COVID-19 vaccine**
 - 6 reports of CVST with thrombocytopenia (platelet counts <150K/mm³) following 6.86 million doses administered
 - Reporting rate of 0.87 cases per million doses administered
- **Pfizer-BioNTech COVID-19 vaccine**
 - 0 reports following 97.9 million doses administered
- **Moderna COVID-19 vaccine**
 - 3 reports following 84.7 million doses administered
 - All 3 with normal platelet counts (150–450K/mm³)

Characteristics of patients with CVST and thrombocytopenia* after Janssen COVID-19 vaccine, N=6

- Median age 33 years (range 18–48)
- Median time to symptom onset 8 days (range 6–13 days)
- All cases occurred in white females
- Current estrogen/progesterone use (n=1)
- Pregnant or post-partum (n=0)
- Pre-existing conditions
 - Obesity (n=3)
 - Hypothyroidism (n=1)
 - Hypertension (n=1)
 - Asthma (n=1)
 - Coagulation disorders (none known)

* Note: Thrombosis usually does not occur in the presence of low platelets; these case presentations are atypical and consistent with cases observed after AstraZeneca COVID-19 vaccine

Initial and late signs and symptoms among CVST patients*, N=6 (patients listed in no particular order)

	Initial features	Late features
Patient 1	Headaches, lethargy	Severe headache, left-sided weakness, vomiting
Patient 2	Headaches	Severe headache, aphasia
Patient 3	Headaches, vomiting, fever	Left arm weakness, right gaze deviation, left neglect
Patient 4	Headaches, chills, myalgias	Severe abdominal pain and fever
Patient 5	Headache, chills, dyspnea, fever	Bruising, unilateral leg swelling, loss of consciousness
Patient 6	Back pain, bruising	Headache, abdominal pain

*All were hospitalized and admitted to the intensive care unit

Locations of CVST, intracerebral hemorrhage, and other thromboses, N=6

Characteristic	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Location of CVST	Right transverse sinus and right sigmoid sinus	Left transverse sinus, left sigmoid sinus, confluence of sinuses, and straight sinus	Superior sagittal sinus, inferior sagittal sinus, and straight sinus	Right transverse sinus and right sigmoid sinus	Right transverse sinus and right sigmoid sinus	Right transverse sinus
Location of intracerebral hemorrhage	Right temporo-parietal lobe	Left temporal lobe	Bilateral frontal lobes, intraventricular	None	None	Occipital lobe
Locations of other thromboses	None	None	None	Portal vein and right pulmonary artery	Bilateral lower extremity VTE, right internal jugular vein	Portal vein

SARS-CoV-2 test results among CVST patients, N=6

	SARS-CoV-2 viral test	SARS-CoV-2 serology
Patient 1	Negative	Not documented
Patient 2	Negative	Nucleocapsid Ab negative
Patient 3	Negative	Not documented
Patient 4	Negative	Not documented
Patient 5	Negative	Unspecified COVID Ab negative
Patient 6	Negative	Unspecified COVID Ab negative

Hematology test results among CVST patients, N=6

	Lowest platelet value (per mm³)	PF4 HIT* antibody test result(s)
Patient 1	12,000	Not done
Patient 2	69,000	Positive
Patient 3	18,000	Positive
Patient 4	127,000	Positive
Patient 5	10,000	Positive
Patient 6	14,000	Positive

*Platelet factor 4 heparin induced thrombocytopenia

Treatment and outcomes among CVST patients, N=6

- Treatment
 - Heparin (n=4)
 - Nonheparin anticoagulants (n=5)
 - Platelets (n=3)
 - Intravenous immunoglobulin (n=3)

- Outcomes
 - Death (n=1)
 - Remain hospitalized (n=3)
 - Intensive care unit (n=2)
 - Discharged home (n=2)

* All 5 of these patients received Argatran

Observed vs. expected CVST cases following Janssen COVID-19 vaccine

- Estimated annual incidence of CVST ~0.5–2 cases per 100,000 population*
- Assumed risk period of 5.6% of a calendar year: (41 days/2) ÷ 365 days
- Doses administered among women aged 20–50 years = 1,402,712 doses (as of Apr 12)

Est. annual background incidence	Obs. cases in women aged 20–50 yrs	Exp. cases in women aged 20–50 yrs	Reporting ratio, women aged 20–50 yrs
0.5 per 100K	6	0.39	15.4
1.0 per 100K	6	0.79	7.6
1.5 per 100k	6	1.18	5.1
2.0 per 100k	6	1.58	3.8

* <https://www.hopkinsmedicine.org/health/conditions-and-diseases/cerebral-venous-sinus-thrombosis>, <http://www.med.umich.edu/1libr/Stroke/SinusVeinThrombosis.pdf>, https://www.nejm.org/doi/10.1056/NEJMra042354?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub, <https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.116.013617>, <https://www.nature.com/articles/nrneurol.2017.104>

Summary

Summary

- CVST is rare, but clinically serious, and can result in substantial morbidity and mortality; not usually associated with thrombocytopenia
- Observed cases following Janssen COVID-19 vaccines appear to exceed expected based on background rates of CVST among women aged 20–50 years (3-fold or greater)
 - All 6 reports were in women age range 18–48 years, all with thrombocytopenia
 - No obvious patterns of risk factors detected
- CVST with thrombocytopenia has not been observed after the two authorized mRNA vaccines
 - 182 million mRNA COVID-19 doses administered with no reported cases to date
- Clinical features of Janssen cases are similar to those observed following the AstraZeneca COVID-19 vaccine in Europe
- Both Janssen and AstraZeneca vaccines contain replication-incompetent adenoviral vectors (human [Ad26.COVS.2.S] for Janssen and chimpanzee [ChAdOx1] for AstraZeneca)

Summary (cont.)

■ For clinicians

- Maintain a high index of suspicion for symptoms that might represent serious thrombotic events or thrombocytopenia in patients who have recently received the Jansen COVID-19 vaccine, including severe headache, backache, new neurologic symptoms, severe abdominal pain, shortness of breath, leg swelling, petechiae (tiny red spots on the skin), or new or easy bruising. Obtain platelet counts and screen for evidence of immune thrombotic thrombocytopenia.
- In patients with a thrombotic event and thrombocytopenia after the Jansen COVID-19 vaccine, evaluate initially with a screening PF4 enzyme-linked immunosorbent (ELISA) assay as would be performed for autoimmune HIT. Consultation with a hematologist is strongly recommended.
- Do not treat patients with thrombotic events and thrombocytopenia following receipt of Janssen COVID-19 vaccine with heparin, unless HIT testing is negative.
- If HIT testing is positive or unable to be performed in patient with thrombotic events and thrombocytopenia following receipt of Jansen COVID-19 vaccine, non-heparin anticoagulants and high-dose intravenous immune globulin should be strongly considered.
- Report adverse events to VAERS, including serious and life-threatening adverse events and deaths in patients following receipt of COVID-19 vaccines as required under the Emergency Use Authorizations for COVID-19 vaccines.

Summary (cont.)

■ For public health

- Encourage healthcare providers and the public to report all serious and life-threatening adverse events and deaths following receipt of COVID-19 vaccines to VAERS as required under the EUAs for COVID-19 vaccines.
- Disseminate information to healthcare providers in your jurisdictions.

■ For the public

- If you have received the Janssen COVID-19 vaccine and develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination, contact your healthcare provider, or seek medical care.
- Report adverse events following receipt of any COVID-19 vaccine to VAERS.
- If you are scheduled to receive the Janssen vaccine, please contact your healthcare provider, vaccination location, or clinic to learn about additional vaccine availability.

How to report an adverse event to VAERS

- Go to vaers.hhs.gov
- Submit a report online
- For help:

Call 1-800-822-7967

Email info@VAERS.org

video instructions

<https://youtu.be/sbCWWhcQADFE>

- Please send records to VAERS ASAP if contacted and asked

– HIPAA permits reporting of protected health information to public health authorities including CDC and FDA



Next steps

- Continue enhanced monitoring in VAERS and other vaccine safety systems (e.g., Vaccine Safety Datalink [VSD])
 - VSD: ~113K Janssen doses administered, 0 cases in risk interval(s)
- Investigate potential cases through detailed clinical reviews/chart reviews
- Refine analyses to better quantify risk

Acknowledgments

We wish to acknowledge the contributions of investigators from the following organizations:

Centers for Disease Control and Prevention

COVID-19 Vaccine Task Force

COVID-19 Vaccine Task Force, Vaccine Safety Team

Immunization Safety Office

Division of Healthcare Quality Promotion

Clinical Immunization Safety Assessment Project

Vaccine Adverse Event Safety Network


Extra

Additional report of patient with non-CVST thromboses and thrombocytopenia after Janssen COVID-19 vaccine*

- 50s y/o female
- History coronary artery disease, hypertension, asthma, COPD
- Developed bruising and leg swelling 11 days after vaccination with Janssen vaccine
- Hospitalized with hematologic event that is non-CVST
 - Left lower extremity deep venous thrombosis
 - Right superficial femoral artery and bilateral iliac artery thrombosis (non-CVST)
- Thrombocytopenia of 15,000/mm³


*Assessment based only on VAERS report; investigation in-progress including obtaining and reviewing medical records

Thrombocytopenic thrombosis after Janssen vaccine



Sara Oliver MD, MSPH
CDC/IDSA COVID-19 Clinician Call
April 17, 2021

Adenovirus vector vaccines



- Concerns for rare clotting events seen after COVID-19 adenovirus vector vaccines
- Clinical syndromes after both vaccines appear similar
- However, extent to which the cases seen after both adenovirus vector vaccines represent the same syndrome is unknown

AstraZeneca (AZ) vaccine

- Last week, EMA's safety committee (PRAC) released report concluding:
 - Strong association and probable causal link between the AZ vaccine and rare clotting events

From the European Union:

- 62 cases of CVST & 24 cases of splanchnic vein thrombosis with thrombocytopenia; 18 were fatal
- Updated numbers: 169 cases of CVST and 53 cases of splanchnic vein thrombosis; 34 million people vaccinated
- Most in females <60 years of age
- Within 2 weeks of AZ vaccine receipt
- Due to different ways vaccine used in each country, cannot exclude age/gender as risk factors

From the United Kingdom:

- 79 cases of thrombosis + thrombocytopenia; 19 were fatal
- 44 cases of CVST (14 fatalities) & 35 cases of other clots (5 fatalities)
- 51 cases were female; 28 were male
- 20.2 million doses given. Estimated risk ~4 per million pop. ('slightly higher incidence' in younger age groups)

CVST: Cerebral Venous Sinus Thrombosis

<https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>

<https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021>

Vaccine-induced immune thrombotic thrombocytopenia

Reports of low platelets (thrombocytopenia) and blood clots (thrombosis) after AZ vaccine in Europe

The NEW ENGLAND JOURNAL of MEDICINE

BRIEF REPORT

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz, M.D., Ph.D., Ingvild H. Sørvoll, M.D., Annika E. Michelsen, Ph.D., Ludvig A. Munthe, M.D., Ph.D., Fridtjof Lund-Johansen, M.D., Ph.D., Maria T. Ahlen, Ph.D., Markus Wiedmann, M.D., Ph.D., Anne-Hege Aarodt, M.D., Ph.D., Thor H. Skattør, M.D., Geir E. Tjønnfjord, M.D., Ph.D., and Pål A. Holme, M.D., Ph.D.

SUMMARY

We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age. All the patients had high levels of antibodies to platelet factor 4–polyanion complexes; however, they had had no previous exposure to heparin. Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia.

Two publications describing cases of thrombotic thrombocytopenia from Germany & Austria, and Norway

Many cases had platelet activating antibodies directed against platelet factor 4 (PF4)

Authors propose syndrome entitled “Vaccine-induced immune thrombotic thrombocytopenia” (VITT)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Andreas Greinacher, M.D., Thomas Thiele, M.D., Theodore E. Warkentin, M.D., Karin Weisser, Ph.D., Paul A. Kyrle, M.D., and Sabine Eichinger, M.D.

ABSTRACT

BACKGROUND

Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder.

METHODS

We assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19. We used a standard enzyme-linked immunosorbent assay to detect platelet factor 4 (PF4)–heparin antibodies and a modified (PF4-enhanced) platelet-activation test to detect platelet-activating antibodies under various reaction conditions. Included in this testing were samples from patients who had blood samples referred for investigation of vaccine-associated thrombotic events, with 28 testing positive on a screening PF4–heparin immunoassay.

AstraZeneca (AZ) vaccine:

Recommendations for use

- EMA's Pharmacovigilance Risk Assessment Committee (PRAC) does not make vaccine policy for the EU; each country weighs the risks and benefits of AZ vaccine individually
- Many countries have adopted age-based recommendations
 - UK: Adults ≥ 30 years of age; April 7, 2021
 - Australia: Adults ≥ 50 years of age; April 8, 2021
 - Other European countries: Adults ≥ 55 to ≥ 70 years of age

Janssen/J&J COVID-19 vaccine:

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine, April 13, 2021

- As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S.
- CDC and FDA are reviewing data involving 6 cases of CVST in combination with low platelets
- “CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to further review these cases and assess their potential significance”.
- “Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution.”

Janssen/J&J COVID-19 vaccine:

HAN released April 13, 2021

Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine



- Recommendations for Clinicians: diagnosis and treatment
- Recommendations for Public Health: case reporting through VAERS
- Recommendations for the Public: clinical signs and symptoms to monitor

Janssen/J&J COVID-19 vaccine:

ACIP Response

- Monday 4/12: Vaccine Safety Technical Group (VaST) meeting
- Tuesday 4/13: ACIP COVID-19 vaccines Work Group meeting
- Wednesday 4/14: Emergency ACIP meeting

Purpose of Emergency ACIP meeting

- Consider implications of reported cases of thrombosis and thrombocytopenia after Janssen/J&J vaccine on vaccination policy

Discussion by the Work Group/ACIP

- Benefit/risk balance for use of the Janssen COVID-19 vaccine
- Review of cerebral venous sinus thrombosis (CVST) cases
- Risk of COVID-19 disease, by sex and age
- COVID-19 vaccines administered, by age
- Janssen vaccine doses administered to date
- Projected supply of COVID-19 vaccines in the US
- Policy options for updated recommendations for use for Janssen COVID-19 vaccine

Janssen Doses Administered to Date

Thrombocytopenic thrombotic events develop ~6-13 days after vaccine receipt

7,233,726 doses administered in the United States

Prior to March 30:

3,466,166 Janssen doses administered
48% of doses



Thrombocytopenic
thrombotic events post-
vaccine likely already
occurred

March 30 to April 13

3,767,560 Janssen doses administered
52% of doses



Thrombocytopenic thrombotic
events post-vaccine may still
occur

What is known so far

- Thrombocytopenic thrombotic events after the AstraZeneca vaccine have occurred
- In the US, 6 cases of CVST reported after receipt of the Janssen COVID-19 vaccine.
- No cases of CVST with thrombocytopenia reported after receipt of either Pfizer and Moderna COVID-19 vaccines
- CVST cases have occurred primarily in younger adults, females
- CVST can be clinically devastating or fatal
- In the US, alternative COVID-19 vaccines (mRNA vaccines) are available
 - Based on current projections, supply of both mRNA vaccines fairly stable for near future

What we do NOT know

- True background incidence of CVST with thrombocytopenia
- Specific risk factors for thrombocytopenic thrombotic events
- Incidence of other thrombotic (non-CVST) cases with thrombocytopenia after Janssen vaccine
- Ability to compare or generalize thrombotic cases after the AstraZeneca vaccine to Janssen vaccine
- True incidence of thrombocytopenic thrombotic events/CVST after a Janssen/J&J COVID-19 vaccine
 - More cases may be identified in the coming days/weeks

Policy discussions from ACIP: Janssen/J&J COVID-19 vaccine



Policy options: Janssen/J&J COVID-19 vaccines

WG Discussion points

- While overall reported cases are rare, once limited to doses administered to age and sex of CVST cases seen, observed cases exceed expected cases
- Given the timing of doses administered (52% of doses administered in the previous 2 weeks), additional cases may be identified over the next 1-2 weeks
- Emphasis that robust safety surveillance is critical
 - Signal detection and evaluation of cases occurred as planned

Policy Options for Janssen Policy Recommendations



Do **not** recommend use
of Janssen vaccine

Recommend use of
Janssen/J&J COVID-19
vaccine in **some**
populations

Recommend use of
Janssen/J&J COVID-19
vaccine in **all adults**
≥18 years of age

Age or gender
specific populations?

ACIP Meeting 4/14

- After discussions regarding the U.S. cases of CVST and thrombocytopenia, ACIP agreed that more information is needed before policy recommendations can be made regarding the Janssen COVID-19 vaccine.

Pathogenesis and Management of Vaccine-induced Immune Thrombotic Thrombocytopenia

Michael B. Streiff, MD
Medical Director

The Johns Hopkins Anticoagulation Management Service and Hemostatic Disorder
Stewardship Program

Johns Hopkins Special Coagulation Laboratory
Professor of Medicine & Professor of Pathology
Johns Hopkins University School of Medicine

Disclosures: Michael Streiff, MD

- Consulting
 - Bristol-Myers Squibb
 - Coagulo Medical Technologies
 - Dispersol
 - Janssen
 - Pfizer
- Research support
 - AHRQ
 - Janssen
 - NIH/NHLBI
 - PCORI

What is Cerebral Venous Sinus Thrombosis?

Clinical characteristics: Thrombosis in the deep or superficial veins of the brain

Incidence: 10-15 cases per million

Mean Age: 35 years


Gender distribution F:M 2.2 : 1

Risk factors: OCP, Thrombophilia, Pregnancy, Cancer, Infections, Surgery

Clinical presentation: Headache, seizures, paresis, papilledema, mental status changes

Diagnosis: Contrast CTV or MRV

Treatment: Anticoagulation, thrombolysis



Capecchi M, Abbattista M, Martinelli I. J Thromb Haemost. 2018 Oct;16(10):1918-1931. Stam J. N Engl J Med. 2005 Apr 28;352(17):1791-8.

Comparison of thrombotic events after Oxford-AZ and Johnson + Johnson COVID-19 vaccines


Oxford-AZ COVID-19 Vaccine Cases

- Median age 36-39 (range 22-54)
- Gender: F:M 13:3
- Associated condition: Estrogens, Obesity, Thrombophilia
- Onset: 5-16 days after vaccine
- Symptoms: Headache, backache, abdominal pain, visual disturbance, hemiparesis
- Thrombosis: Cerebral , Splanchnic, IVC, PE, Multiorgan
- Platelet nadir: 8-107K
- Heparin-PF4 EIA- positive (Hep neutral +)
- Plt-Activation assay + with UFH and buffer

Johnson + Johnson COVID-19 Vaccine cases


- Age range teens to 40s
- Gender F:M 7:0
- Pre-existing conditions: Obesity, Estrogens
- Onset: 6-13 days
- Symptoms: Headache, lethargy, back pain, abdominal pain, neurologic sx
- Thrombosis: Cerebral veins, splanchnic
- Platelet nadir: 10-127K
- Heparin-PF4 EIA: positive
- Plt Activation assay Neg, Unknown

Proposed Pathogenesis of Vaccine-Induced Immune Thrombotic Thrombocytopenia



Hogan M, Berger JS. Vasc Med. 2020 Apr;25(2):160-173.

Proposed Pathogenesis of Vaccine-Induced Immune Thrombotic Thrombocytopenia



Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A, Alberio L. J Clin Med. 2021 Feb 10;10(4):683.

Management of Vaccine Induced Immune Thrombotic Thrombocytopenia

- Maintain a high index of suspicion for any patient that presents with symptoms of a venous or arterial thrombotic event in association with thrombocytopenia after recent (within 3 weeks) administration of the J+J COVID-19 vaccine
- Order the following studies in patients with a confirmed thrombotic event
 - Heparin-PF4 ELISA assay and serotonin release assay (with therapeutic and high concentrations of heparin and buffer control)
 - D dimer, fibrinogen and antiphospholipid panel (aPTT, dRVVT, cardiolipin, beta 2 GP1 abs)
- Treat the patient as if they have heparin-induced thrombocytopenia
 - Low risk of bleeding: Options include bivalirudin, argatroban, apixaban, rivaroxaban, fondaparinux
 - High risk of bleeding: bivalirudin or argatroban
 - Thrombocytopenia: add IVIG 1g/kg daily X 2, avoid platelet transfusions
 - Avoid warfarin

New FAQ from the American Society of Hematology

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

(Version 1.1; last updated April 16, 2021)

Input from: James Bussell, MD; Jean M. Connors, MD; Douglas B. Cines, MD; Cynthia E. Dunbar, MD; Laura C. Michaelis, MD; Lisa Baumann Kreuziger, MD; Agnes Y. Y. Lee, MD, MSc; Ingrid Pabinger, MD

On April 13, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention suggested pausing administration of the AD26.COV2.S Johnson & Johnson (JJ) vaccine to allow investigation of several cases of a severe clotting and thrombocytopenia syndrome being termed "vaccine-induced immune thrombotic thrombocytopenia (VITT)" occurring post-vaccination. This announcement comes on the heels of the initial reports of VITT in individuals receiving the CHaDOx1 nCov-19 AstraZeneca (AZ) vaccine outside the United States. Clinical and laboratory characteristics of VITT have recently been reported.^{1,2,3} The incidence of this constellation of findings appears extremely low following either vaccine, with causality not established.

There is no information to date on any increased risk for VITT in patients with blood diseases and/or pre-existing risk factors for thrombosis or autoimmunity. Based on current information, the consensus is that the risk of COVID-19 disease, including thrombosis, far outweighs the extremely rare risk of VITT associated with highly efficacious vaccines.⁴

This FAQ is designed to provide an overview of considerations around the diagnosis and treatment of VITT and will be updated as more information becomes available. Hematologists with expertise in hemostasis should be consulted early, and many institutions will devise algorithms based on local laboratory testing availability and practices.

Q1. What is vaccine-induced immune thrombotic thrombocytopenia (VITT)?

A syndrome characterized by 1) thrombosis, particularly at unusual sites including cerebral sinus venous thrombosis (CSVT)/splanchnic thrombosis; 2) mild to severe thrombocytopenia; and 3) positive PF4-heparin ELISA and platelet activation assays was recently described in patients vaccinated five to 16 days previously with the ChAdOx1 nCov-19 AZ vaccine, utilized extensively in the United Kingdom, Europe, and Canada, but not yet available in the United States.^{1,2} Patients in these reports were primarily younger than 55 years, and more than 80 percent were female. None had received recent heparin, and few had other known risk factors for thrombosis. Many of the patients were

Next Steps



Next Steps

- CDC will convene another ACIP meeting **Friday, April 23**, from ~11-5pm EST
- In preparation for the ACIP meeting, CDC will:
 - Identify and evaluate any cases in the risk window (1-2 weeks after getting vaccinated)
 - Identify and evaluate any past cases that might come to light because of the announcements (stimulated reporting)
 - Formulate more precise data around observed versus expected rates of thrombotic events after Janssen vaccine
 - Undergo a formal risk benefit analysis

Janssen/J&J COVID-19 vaccine: HAN released April 13, 2021

Cases of Cerebral Venous Sinus Thrombosis with
Thrombocytopenia after Receipt of the Johnson &
Johnson COVID-19 Vaccine



- Recommendations for Clinicians: diagnosis and treatment
 - Evaluate patients with a screening PF4 enzyme-linked immunosorbent (ELISA) assay as would be performed for autoimmune HIT. Consultation with a hematologist is strongly recommended.
 - Do not treat with heparin, unless HIT testing is negative
- Recommendations for Public Health: case reporting through VAERS
 - Encourage healthcare providers and the public to report all serious and life-threatening adverse events and deaths following receipt of COVID-19 vaccines to VAERS
- Recommendations for the Public: clinical signs and symptoms to monitor
 - Contact healthcare provider, or seek medical care if you develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination with the J&J COVID-19 vaccine

How to report an adverse event to VAERS

- Go to vaers.hhs.gov
- Submit a report online
- For help:

Call [1-800-822-7967](tel:1-800-822-7967)

Email info@VAERS.org


video instructions

<https://youtu.be/sbCWhcQADFE>

- Please send records to VAERS ASAP if contacted and asked

— HIPAA permits reporting of protected health information to public health authorities including CDC and FDA





For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Q&A and Discussion

Sara Oliver, MD, MSPH

LCDR, U.S. Public Health Service
Co-Lead, COVID-19 Work Group of the Advisory Committee on
Immunization Practices
Centers for Disease Control and Prevention

Michael B. Streiff, MD

Medical Director
The Johns Hopkins Anticoagulation Management Service and
Hemostatic Disorder Stewardship Program
Johns Hopkins Special Coagulation Laboratory
Professor of Medicine & Professor of Pathology
Johns Hopkins University School of Medicine

Tom Shimabukuro, MD, MPH, MBA

Captain, U.S. Public Health Service
Deputy Director
Immunization Safety Office
Centers for Disease Control and Prevention

John Su, MD, PhD, MPH

VAERS Team Lead
Centers for Disease Control and Prevention


Links from Today's Slides

- Slide 8: Platelets and thrombocytopenia (low platelets): <https://www.mayoclinic.org/diseases-conditions/thrombocytopenia/symptoms-causes/syc-20378293>
- Slide 9: AstraZeneca COVID-19 EMA Announcement, 7/4/21: <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>
- Slide 11: CDC Health Alert: <https://emergency.cdc.gov/han/2021/han00442.asp>
- Slide 16: Vaccine Adverse Event Reporting System (VAERS): <http://vaers.hhs.gov>
- Slide 17, 18: CDC COVID-19 Data Tracker: <https://covid.cdc.gov/covid-data-tracker/#vaccinations>
- Slide 25: Observed vs. expected CVST cases following Janssen COVID-19 vaccine: <https://www.hopkinsmedicine.org/health/conditions-and-diseases/cerebral-venous-sinus-thrombosis>, <http://www.med.umich.edu/1libr/Stroke/SinusVeinThrombosis.pdf>, https://www.nejm.org/doi/10.1056/NEJMra042354?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub, <https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.116.013617>, <https://www.nature.com/articles/nrneurol.2017.104>
- Slide 37: AstraZeneca vaccine: <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>, <https://www.gov.uk/government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine-7-april-2021>
- Slide 38: Vaccine-induced immune thrombotic thrombocytopenia- NEJM articles: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=featured_home, https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=featured_home
- Slide 40: Joint CDC/FDA statement on J&J Vaccine: <https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html>
- Slide 41, 61: J&J Vaccine HAN: <https://emergency.cdc.gov/han/2021/han00442.asp>
- Slide 48: ASH FAQ on vaccine-induced immune thrombotic thrombocytopenia: <https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia>

COVID-19 Real-Time Learning Network

Brought to you by CDC and IDSA

An online community bringing together information and opportunities for discussion on latest research, guidelines, tools and resources from a variety of medical subspecialties around the world.



Specialty Society Collaborators

American Academy of Family Physicians
 American Academy of Pediatrics
 American College of Emergency Physicians
 American College of Physicians
 American Geriatrics Society
 American Thoracic Society
 Pediatric Infectious Diseases Society
 Society for Critical Care Medicine
 Society for Healthcare Epidemiology of America
 Society of Hospital Medicine
 Society of Infectious Diseases Pharmacists

www.COVID19LearningNetwork.org

@RealTimeCOVID19

#RealTimeCOVID19

CDC-IDSA Partnership: Clinical Management Call Support

FOR WHOM?


- Clinicians who have questions about the clinical management of COVID-19

WHAT?

- Calls from clinicians will be triaged by CDC to a group of IDSA volunteer clinicians for peer-to-peer support

HOW?

- Clinicians may call the main CDC information line at 800-CDC-INFO (800-232-4636)
- To submit your question in writing, go to www.cdc.gov/cdc-info and click on Contact Form




IDSA
Infectious Diseases Society of America

cdc.gov/coronavirus

Continue the
conversation on Twitter

@RealTimeCOVID19
#RealTimeCOVID19



We want to hear from you!
Please complete the post-call survey.

Next Call: **Sat., April 24**

A recording of this call will be posted at
www.idsociety.org/cliniciancalls
-- library of all past calls now available --

Contact Us:

Dana Wollins (dwollins@idsociety.org)

Deirdre Lewis (dlewis@idsociety.org)